Proving the design space: Advancing the development of autoinjector combination products

In the October edition of ONdrugDelivery magazine, SHL Medical and Stevanato Group jointly published an article titled “Proving the Design Space: Advancing the Development of Syringe-Device Combinations.” Featured in the Prefilled Syringes and Injection Devices edition, the piece was co-authored by Courtney Nicholas Sutton, Head of Portfolio Strategy at SHL Medical, and Enrico Barichello, Product Manager of Syringe Platform at Stevanato Group. 

In the article, the authors highlight the pivotal role that collaboration between primary container and delivery device manufacturers can play by showcasing how platform-based solutions, rigorously tested across the critical integration factors, can streamline the path to market for innovative patient-centric biologic therapies.  

As demand for at-home administration of biologics and other complex therapies continues to rise, the need for reliable, patient-friendly delivery systems is more critical than ever. The article addresses key challenges posed by complex formulations and emphasizes the value of ensuring compatibility between primary container and autoinjector at a platform level. The authors present performance data of SHL Medical’s Molly® autoinjector with Stevanato Group’s Alba® and Nexa® prefilled syringes – illustrating how platform-based compatibility offers pharmaceutical partners a comprehensive and de-risked solution for a broad range of drug formulation. Data were collected at both the syringe and device platform levels across various configurations – from thin wall to special thin wall, 25G to 27G, and ½ inch to 8 mm needles with formulations up to 50 cP, demonstrating full compatibility between Molly autoinjector and Alba® and Nexa® portfolio of glass syringes. 

Read the full article to explore how SHL Medical and Stevanato Group are mitigating integration risks and accelerating time to market through strategic collaboration.